S

Seagen

3431 employees

Seagen is a clinical-stage biotechnology company dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.

Investor insights

Sectors invested in

Biotechnology2
kinase inhibitors1
Pharmaceutical1
Biopharma1
Medical1
Health Care1
Therapeutics1
Systemic Mastocytosis1
Oncology1
gastrointestinal stromal tumors (GIST)1

Funding rounds participated in

$35M sweet spot round size

Most of their 2 investments are in rounds between $5M and $65M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Blood cancers
Conjugation Chemistry
Pharmaceutical
Drug development
Monoclonal antibody-based therapies for cancer
Bladder cancer
Cancer drug development
Non-Hodgkin lymphoma
Health Care
Antibody-Drug Conjugates
Therapeutics
Hodgkin lymphoma

Date founded

1998

Investments made

P

Pieris AG raised $5M on January 10, 2023

Investors: Seagen

C

Cogent Biosciences raised $65M on June 11, 2015

Investors: Jennison Associates LLC, Sectoral Asset Management, Sanofi Ventures, Novo Holdings, Wellington Management, F-Prime Capital Partners, Cowen Inc., New Leaf Venture Partners and Seagen

FAQ